Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
April 15, 2024 07:00 ET
|
Walden Biosciences, Inc.
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney...
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 07, 2024 16:12 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 23, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
December 18, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 18, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
June 05, 2023 07:48 ET
|
Walden Biosciences, Inc.
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE,...
Walden Biosciences Announces Participation at October Investor Conferences
October 13, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Participation in Citi’s 17th Annual BioPharma Conference
August 31, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 24, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...